{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:55:53Z","timestamp":1790672153447,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"A.C.Camargo Cancer Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Talquetamab (TAL), a first-in-class bispecific antibody targeting GPRC5D and CD3, has demonstrated high efficacy in heavily pretreated relapsed and refractory multiple myeloma (RRMM), achieving response rates of approximately 70%. However, TAL is frequently associated with on-target, off-tumor oral toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to review the features of oral toxicities related to TAL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive review of the recent literature on TAL-associated oral toxicities was conducted. Extracted data included time to onset, incidence, severity grading, and reported management strategies for these adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Oral effects are hypothesized to arise from immune activation against epithelial cells expressing GPRC5D in the tongue, salivary glands, and hard keratinized tissues. Clinical studies, including the MonumenTAL-1 trial, have reported dysgeusia in up to 72% of patients, dry mouth in 39%, and dysphagia in 24% of patients. Such toxicities typically arise within a few weeks of initiating TAL therapy and tend to persist. They can significantly impair nutrition and quality of life, often leading to weight loss exceeding 6% of baseline body weight. Current management is largely supportive, including corticosteroid mouthwashes, saliva stimulants, nutritional counseling, and TAL dose adjustments, with limited efficacy. The ongoing TALISMAN trial is evaluating prophylactic interventions such as dexamethasone mouthwash and pregabalin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Oral toxicities often emerge early and may persist throughout the therapy. Consequently, early recognition, preventive care, and multidisciplinary management are essential to mitigate oral complications and preserve quality of life in patients receiving TAL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10583-4","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:10:24Z","timestamp":1773987024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["On-target, off-tumor oral toxicities of talquetamab in heavily pretreated multiple myeloma"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-1536","authenticated-orcid":false,"given":"Fabio Abreu","family":"Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Perez Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella Chagas","family":"Jaguar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayr Schmidt","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"5","key":"10583_CR1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R et al (2022) LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia 36(5):1371\u20131376. https:\/\/doi.org\/10.1038\/s41375-022-01531-2","journal-title":"Leukemia"},{"key":"10583_CR2","doi-asserted-by":"publisher","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, PERSEUS Trial Investigators et al (2024) Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2312054","DOI":"10.1056\/NEJMoa2312054"},{"issue":"8","key":"10583_CR3","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"issue":"2","key":"10583_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/antib12020038","volume":"12","author":"R Khanam","year":"2023","unstructured":"Khanam R, Ashruf OS, Waqar SHB, Shah Z, Batool S, Mehreen R et al (2023) The role of bispecific antibodies in relapsed refractory multiple myeloma: a systematic review. Antibodies (Basel) (2):38. https:\/\/doi.org\/10.3390\/antib12020038","journal-title":"Antibodies (Basel)"},{"issue":"3","key":"10583_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ejh.14353","volume":"114","author":"C Labanca","year":"2025","unstructured":"Labanca C, Martino EA, Vigna E, Bruzzese A, Mendicino F, Lucia E et al (2025) Talquetamab in multiple myeloma: efficacy, safety, and future directions. Eur J Haematol 114(3):386\u2013399. https:\/\/doi.org\/10.1111\/ejh.14353","journal-title":"Eur J Haematol"},{"key":"10583_CR6","doi-asserted-by":"publisher","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P et al (2022) Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2204591","DOI":"10.1056\/NEJMoa2204591"},{"key":"10583_CR7","unstructured":"Janssen Biotech, Inc. TALVEY\u2122 (talquetamab-tgvs) prescribing information. https:\/\/www.talvey.com.\u00a0Accessed 5 Mar 2023"},{"issue":"4","key":"10583_CR8","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A et al (2025) Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol 12(4):e269\u2013e281. https:\/\/doi.org\/10.1016\/S2352-3026(24)00385-5","journal-title":"Lancet Haematol"},{"issue":"3","key":"10583_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s12185-025-03991-5","volume":"122","author":"S Iida","year":"2025","unstructured":"Iida S, Sunami K, Ito S, Yuda J, Fujikawa E, Takamoto M et al (2025) Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed\/refractory MM. Int J Hematol 122(3):421\u2013433. https:\/\/doi.org\/10.1007\/s12185-025-03991-5","journal-title":"Int J Hematol"},{"issue":"1","key":"10583_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08233-0","volume":"32","author":"AMGA Laheij","year":"2024","unstructured":"Laheij AMGA, van de Donk NWCJ (2024) Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab. Support Care Cancer 32(1):20. https:\/\/doi.org\/10.1007\/s00520-023-08233-0","journal-title":"Support Care Cancer"},{"issue":"2","key":"10583_CR11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jaad.2023.08.094","volume":"90","author":"M Lery","year":"2024","unstructured":"Lery M, Perrot A, Ortiz-Brugu\u00e9s A, Vigarios E, Anghel D, Bories P, Sibaud V (2024) Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab. J Am Acad Dermatol 90(2):376\u2013377. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.094","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10583_CR12","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/ddg.15502","volume":"22","author":"M Mansilla-Polo","year":"2024","unstructured":"Mansilla-Polo M, Mart\u00edn-Torregrosa D, Mart\u00ednez-Cozar V, Arnao-Herraiz M, Botella-Estrada R (2024) Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review. JDDG J Dtsch Dermatol Ges 22(9):1282\u20131286. https:\/\/doi.org\/10.1111\/ddg.15502","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"14","key":"10583_CR13","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1080\/10428194.2025.2556175","volume":"66","author":"N Gross Even-Zohar","year":"2025","unstructured":"Gross Even-Zohar N, Aumann S, Shaulov A, Haran A, Nachmias B, Lebel E, Lehmann-Werman R, Gatt ME (2025) First case report of talquetamab use in AL amyloidosis. Leuk Lymphoma 66(14):2618\u20132623. https:\/\/doi.org\/10.1080\/10428194.2025.2556175","journal-title":"Leuk Lymphoma"},{"key":"10583_CR14","doi-asserted-by":"publisher","unstructured":"Kayahara GM, Espinhosa RB, da Silva SN, Pereira MAS, Bernab\u00e9 DG, Miyahara GI et al (2025) Talquetamab-induced dysgeusia successfully treated with photobiomodulation therapy. Laryngoscope. https:\/\/doi.org\/10.1002\/lary.32445","DOI":"10.1002\/lary.32445"},{"issue":"3","key":"10583_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/s0167-4781(01)00197-x","volume":"1518","author":"H Br\u00e4uner-Osborne","year":"2001","unstructured":"Br\u00e4uner-Osborne H, Jensen AA, Sheppard PO, Brodin B, Krogsgaard-Larsen P, O\u2019Hara P (2001) Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D. Biochim Biophys Acta 1518(3):237\u201348. https:\/\/doi.org\/10.1016\/s0167-4781(01)00197-x","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10583_CR16","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV et al (2021) Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv 5(8):2196\u20132215. https:\/\/doi.org\/10.1182\/bloodadvances.2020003805","journal-title":"Blood Adv"},{"issue":"3","key":"10583_CR17","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","volume":"122","author":"S Inoue","year":"2004","unstructured":"Inoue S, Nambu T, Shimomura T (2004) The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Invest Dermatol 122(3):565\u201373. https:\/\/doi.org\/10.1046\/j.0022-202X.2004.12628.x","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10583_CR18","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/S2152-2650(21)02229-1","volume":"21","author":"IC Rachel Goldsmith","year":"2021","unstructured":"Rachel Goldsmith IC, Jing Ying Ma XY, Ping Peng VC (2021) P-095: normal human tissue expression of G-protein coupled receptor 5D (GPRC5D), a promising novel target for multiple myeloma, is restricted to plasma cells and hard keratinized tissues. Clin Lymphoma Myeloma Leuk 21(2):S91. https:\/\/doi.org\/10.1016\/S2152-2650(21)02229-1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10583_CR19","unstructured":"The Human Protein Atlas- https:\/\/www.proteinatlas.org\u00a0Accessed Feb 17, 2026"},{"issue":"1","key":"10583_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/nu15010226","volume":"15","author":"M Pellegrini","year":"2023","unstructured":"Pellegrini M, Merlo FD, Agnello E, Monge T, Devecchi A, Casalone V et al (2023) Dysgeusia in patients with breast cancer treated with chemotherapy-a narrative review. Nutrients 15(1):226. https:\/\/doi.org\/10.3390\/nu15010226","journal-title":"Nutrients"},{"key":"10583_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0000000000001537","author":"H Du","year":"2025","unstructured":"Du H, Jiao Q, Liu C, Wu X, Guo J, Zheng H et al (2025Sep 22) Dynamic changes in symptom clusters and symptom networks in patients with multiple myeloma: a cross-lagged network analysis. Cancer Nurs. https:\/\/doi.org\/10.1097\/NCC.0000000000001537","journal-title":"Cancer Nurs"},{"key":"10583_CR22","doi-asserted-by":"publisher","unstructured":"Naqvi S, Shrestha A, Alzubi M, Alrawabdeh J, Thanendrarajan S, Zangari M et al (2024Jul 3) Weight loss and dysgeusia in relapsed\/refractory multiple myeloma patients treated with talquetamab. EJHaem 5(4):789\u2013792. https:\/\/doi.org\/10.1002\/jha2.971.Erratum.In:EJHaem.2025May19;6(3):e70052.doi:10.1002\/jha2.70052","DOI":"10.1002\/jha2.971.Erratum.In:EJHaem.2025May19;6(3):e70052.doi:10.1002\/jha2.70052"},{"issue":"7","key":"10583_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01386-7","volume":"15","author":"S Al Hadidi","year":"2025","unstructured":"Al Hadidi S, Szabo A, Mohan Lal B, Bag A, Zhen S, Ogunsesan Y et al (2025) Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J 15(7):196. https:\/\/doi.org\/10.1038\/s41408-025-01386-7","journal-title":"Blood Cancer J"},{"key":"10583_CR24","doi-asserted-by":"publisher","unstructured":"Popat R, Laheij A, van de Donk NW, Doty RL, Omel J, Lipe B, Rasche L et al (2025)\u00a0Prophylactic interventions for oral toxicities with the GPRC5D\u00d7CD3 bispecific antibody talquetamab in relapsed\/refractory multiple myeloma: an update on the open-label, phase 2, randomized TALISMAN study. (NCT06500884). J Clin Oncol 43, TPS7565. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.TPS7565","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7565"},{"issue":"10","key":"10583_CR25","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","volume":"24","author":"A Chari","year":"2024","unstructured":"Chari A, Krishnan A, Rasche L, Ye JC, Garfall A, Popat R et al (2024) Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab. Clin Lymphoma Myeloma Leuk 24(10):665-693.e14. https:\/\/doi.org\/10.1016\/j.clml.2024.05.003","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10583_CR26","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1080\/03007995.2024.2387183","volume":"40","author":"C Schinke","year":"2024","unstructured":"Schinke C, Dhakal B, Mazzoni S, Shenoy S, Scott SA, Richards T et al (2024) Real-world experience with clinical management of talquetamab in relapsed\/refractory multiple myeloma: a qualitative study of US healthcare providers. Curr Med Res Opin 40(10):1705\u20131711. https:\/\/doi.org\/10.1080\/03007995.2024.2387183","journal-title":"Curr Med Res Opin"},{"issue":"29","key":"10583_CR27","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ et al (2022) GPRC5D-Targeted CAR T cells for myeloma. N Engl J Med 387(29):1196\u20131206. https:\/\/doi.org\/10.1056\/NEJMoa2209900","journal-title":"N Engl J Med"},{"issue":"10","key":"10583_CR28","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1016\/S2352-3026(25)00176-0","volume":"12","author":"L Jin","year":"2025","unstructured":"Jin L, Gu S, Ruan Q, Lu J, Qiang W, He H et al (2025) GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol 12(10):e798\u2013e807. https:\/\/doi.org\/10.1016\/S2352-3026(25)00176-0","journal-title":"Lancet Haematol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10583-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10583-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10583-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:41:59Z","timestamp":1776235319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10583-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10583"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10583-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"347"}}